Efficacy and safety of Shu-gan-qing-re formula for generalized anxiety disorder: study protocol for a multi-center, prospective, double-blind, double-dummy, randomized controlled trial

Pei Chen†, Hong Zhu†, Yanzhe Ning, Dongqing Yin and Hongxiao Jia*

Abstract

Background: Generalized anxiety disorder (GAD) is a persistent and common mental disorder that entails significant impairments in role functioning and quality of life. Currently available effective interventions include psychological therapies, self-help approaches, and pharmacological treatments, which do not quite meet clinical needs, and the ideal anxiolytic is still being sought. Shu-gan-qing-re (SGQR) formula, a Chinese patent medicine, has been well received by patients with GAD in Chinese clinical practice for years. The present prospective, double-blind, double-dummy, randomized controlled trial is designed to investigate the efficacy and safety of SGQR formula for GAD.

Methods/design: A total of 200 eligible participants will be recruited from four hospitals in different parts of China. They will be randomly assigned to either the study group or the control group in a ratio of 1:1. Participants allocated to the study group will receive SGQR formula and buspirone placebo, while buspirone and SGQR placebo will be applied in the control group. Six scheduled visits will be conducted over the course of 8 weeks. Outcome measurements include Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale-17 (HAMD-17), Clinical Global Impression-Improvement Scale (CGI-I), Traditional Chinese Medicine Syndrome Scale for GAD, and pro-inflammatory cytokine tests: interleukin-1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha. Adverse reactions will be evaluated by using the Treatment Emergent Symptom Scale (TESS). Safety outcomes and adverse events will also be recorded.

Discussion: The study will provide scientific and objective assessments for the efficacy and safety of SGQR formula for patients with GAD, hopefully offering clinicians an alternative approach to GAD.

(Continued on next page)
**Background**

Generalized anxiety disorder (GAD) is a persistent and common disorder characterized by feelings of threat, restlessness, irritability, sleep disturbance, tension, and symptoms such as palpitations, dry mouth, and sweating [1]. An epidemiological study in China suggested that the illness has a lifetime prevalence of 0.3% and a 12-month prevalence of 0.2% (the highest prevalence is in the 50- to 64-year-old group) but shows no gender difference [2]. The high prevalence of concurrent psychiatric disorders makes the diagnosis of GAD difficult, possibly contributing to the different epidemiological results of China, Europe, and the US [3, 4]. Comorbidity with at least one other mental disorder at some point troubles the majority of patients with GAD, most commonly with major depressive disorder [1, 5]. Besides, GAD is associated with considerable economic costs owing to work productivity loss and high medical resource use. The role impairments of pure GAD are similar in magnitude to those of major depressive disorder [5].

GAD has a relapsing course, and treatments rarely result in complete resolution of symptoms. In the short to medium term, effective intervention includes psychological therapies, such as cognitive behavioral therapy; self-help approaches based on cognitive behavioral therapy principles; and pharmacological treatments [1]. Until the mid-1980s, pharmacological treatment options consisted primarily of benzodiazepines, which later became an effective short-term therapy in consideration of their abuse potential. For patients requiring long-term treatment, buspirone and some newer antidepressants became the alternatives. Nevertheless, the mild efficacy combined with a slow onset of action dampened the satisfaction with buspirone, whereas antidepressants, mainly selective serotonin reuptake inhibitors (including paroxetine), brought both efficacy and lots of adverse effects [6]. The search for the ideal anxiolytic has never stopped.

Traditional Chinese medicine (TCM) is the most popular alternative and complementary medicine in China. It has a long history in the treatment of mental disorders and has favorable clinical effectiveness. According to the theory of TCM, anxiety results mainly from the stagnation of the liver qi, and inner heat emerges as a result. Shu-gan-qing-re (SGQR) formula is tailored from famous TCM prescriptions: Xiao-yao powder and Gan-mai-da-zao decoction. It is composed of Radix Paeoniae Alba, Radix Bupleuri, Angelica Sinensis, and seven other herbas and functions by smoothing the liver qi. SGQR formula can help to relieve anxiety and has been used in Chinese clinical practice for years.

The present multi-center, prospective, double-blind, double-dummy, randomized controlled trial is designed to investigate the efficacy and safety of SGQR formula, setting buspirone as the control treatment. We hope that, through this rigorously designed study, we can provide scientific and objective assessments for the efficacy and safety of SGQR formula for patients with GAD and possibly offer the world an alternative anxiolytic.

**Methods/design**

**Study design**

This is a multi-center, prospective, double-blind, double-dummy, randomized controlled trial. The flowchart of the study is presented in Fig. 1.

**Ethical issues**

The clinical trial has been registered on the Chinese Clinical Trial Registry (ChiCTR-IPR-17013058). The study protocol (version 2.0 in August 2017) has been approved by the research ethics committee of Beijing Anding Hospital, Capital Medical University ((2017)63-201772FS-2). The research ethics committee will also be responsible for supervising all procedures of the study, including participant recruitment, randomization, conduction, and data storage. In case of any changes to the study protocol, we will submit a written application to the research ethics committee. They will decide whether it is acceptable to make the change.

**Participant recruitment**

A total of 200 eligible participants will be recruited from four hospitals in different parts of China: Beijing Anding Hospital, Xiamen Xianyue Hospital, Tangshan 5th Hospital, and Zhumadian 2nd People’s Hospital. Both inpatients and outpatients will be screened for participation from November 2017.

**Informed consent**

Potentially eligible patients will be invited to take part in our study. Prior to enrollment, researchers will fully introduce the detailed procedures of the study to the patients. All questions and concerns raised about the study
will be addressed at length. Patients will also be informed of the probable benefits and potential risks and assured that participation is entirely voluntary. Patients who meet all of the inclusion criteria and none of the exclusion criteria will be enrolled after providing written informed consent. The personal information of all the participants will always be kept confidential.

Criteria

Inclusion criteria

Participants meeting all of the following criteria will be enrolled: (1) inpatients or outpatients with GAD diagnosed in accordance with the International Classification of Disease-10; (2) those with a diagnosed TCM pattern of liver-qi stagnation transforming into fire, which usually manifests as irritability, constriction in the chest, hypochondriac distention, gastric discomfort with acid regurgitation, dry mouth or bitter taste in the mouth (or both), constipation, headache, conjunctival congestion, tinnitus, reddened tongue with yellow fur, and rapid pulse; (3) ages between 18 and 65 (no limitation on gender); (4) Hamilton Anxiety Rating Scale (HAM-A) scores between 14 and 39 (inclusive) at screening and baseline; and (5) written informed consent obtained either personally or by proxy.

Exclusion criteria

Participants meeting any one of the exclusive criteria will not be enrolled: (1) patients with serious suicidal tendencies; (2) patients with glaucoma; with severe or unstable internal medical conditions involving mainly the heart, liver, kidney, endocrine system, or the blood; or with diseases that may induce acute or chronic abnormal levels of pro-inflammatory cytokines (systemic lupus

Fig. 1 Study design
erythematous, ulcerative colitis, etc.; (3) history of epilepsy (hyperpyretic convulsion in the childhood excepted); (4) alcohol or drug dependence in the previous year; (5) anxiety resulting from other mental or physical disorders; (6) pregnant or breastfeeding women or women who plan to conceive during the study period; (7) history of severe drug allergy or allergy to buspirone; (8) participation in other clinical drug trials in the previous 30 days; (9) intake of monoamine oxidase inhibitor or buspirone in the previous 4 weeks; (10) regular medicine intake cannot be guaranteed because of being uncared or other reasons; (11) a reduction of the HAM-A score of at least 25% at baseline compared with the screening time; and (12) a Hamilton Depression Rating Scale-17 (HAMD-17) score of more than 7 at screening.

Randomization and allocation concealment
Eligible participants will be randomly assigned to either the study group or the control group in a ratio of 1:1. A computer-generated random allocation sequence will be produced by an independent statistician using SAS software (SAS Institute, Cary, NC, USA). Based on the allocation sequence, drug packages will be labeled serially. Participants will receive the corresponding drug package in the order of recruitment. The complete random sequence will be kept by the primary researcher in Beijing Anding Hospital. Emergency envelopes containing the random allocation individually will be prepared for each center, which can be unsealed only in the case of serious adverse events.

Blinding
Pharmacists in charge of labeling the drug packages do not take part in the conduction of the trial. Participants and researchers responsible for screening, recruitment, dispensing medicine, and outcome assessment will all be blind to the group allocation. Statistical analysis will be conducted by independent statisticians who will know only the group codes but not the corresponding interventions.

Interventions
Participants allocated to the study group will receive SGQR formula and buspirone placebo, while buspirone and SGQR placebo will be applied in the control group. The drug and its matching placebo will have a similar appearance, weight, and taste. SGQR formula and placebos will be provided by Tiansheng Taifeng Pharm Co. Ltd. (Lhasa, Tibet, China), and buspirone will be manufactured by Enhua Pharm Co. Ltd. (Xuzhou, Jiangsu, China).

SGQR formula is prepared in the form of condensed pills. The pills will be packed at a unit of 4 grams, whose ingredient is equivalent to Radix Paeoniae Alba 1.14 g, Radix Bupleuri 0.86 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g, Radix Curcumae 0.57 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Cortex Albiziae 0.69 g, Radix Glycyrrhiza 0.34 g, Trichosanthis Kirilowii Makl. 0.69 g, Poria Cocos 0.69 g, Bulbus Lilii 0.69 g, Angelica Sinensis 0.57 g.

In the first week of intervention, participants will be prescribed the starting dosage for the first three days and the low dosage for the remaining four days. From the second week on, the dosage will be adjusted by the researchers. The recommended indicator for doubling to high dosage is a reduction of not more than 25% of the HAM-A score compared with the baseline after the first week’s intervention, keeping low dosage otherwise. Moreover, high dosage and low dosage can be alternated anytime during the intervention period in accordance with patient’s reaction to the previous treatment.

Drugs and placebos covering the whole course of treatment for each participant will be packed uniformly and individually. In each center, there will be a pharmacist responsible for dispensing the prescription. At every visit, participants will receive the drugs scheduled for the next intervention period, and the drugs left from the previous period will be returned. The dosage will be explained to the participants orally and in writing and also recorded in a medical booklet. Medication compliance will be calculated accordingly. The scheduled duration of treatment is 8 weeks unless a serious adverse event happens or the participant quits. Non-pharmacologic care is permitted but other psychiatric medication is prohibited. Administration and dosage of concomitant medication for physical conditions will be permitted and recorded in detail.

Any question raised by the participants will be answered to promote completion. The detailed study schedule is listed in Fig. 2.

Outcome measurements
Outcome measurements are scheduled at screening, baseline, and the end of weeks 1, 2, 4, and 8.

Basic characteristic variables
Basic data of all the participants, including name, gender, date of birth, marital status, educational level, date of diagnosis, and medical history, will be collected. General physical examination results, including vital signs (body temperature, blood pressure, respiratory rate, and heart rate), will also be recorded. Concomitant medication will be inquired about and documented at every visit.
**Primary outcome**

HAM-A, which is one of the first and most widely used rating scales to measure the severity of anxiety symptoms, will be set as the primary outcome [7]. There are 14 items in the HAM-A, which incorporate groups of symptoms (such as fears, autonomic symptoms, and respiratory symptoms) rather than specific, single symptoms. Each item is rated from 0 to 4; the higher the score, the worse the situation. The good reliability and validity of HAM-A make it a standard interviewer-administered instrument [8].

**Secondary outcomes**

HAMD-17 is set as one of the secondary outcomes because comorbidity of depression and anxiety is rather common in health-care settings [9]. HAMD-17, a multi-dimensional rating scale that covers a range of clinical features associated with depression, is the standard efficacy outcome for depression severity evaluation, treatment response, and remission measurement [10, 11]. The higher the HAMD-17 score, the worse the situation.

Another secondary outcome focuses on the improvement in overall symptom severity and functioning, measured by using the Clinical Global Impression-Improvement Scale (CGI-I), which consists of a 7-point global rating (1 = very much improved, 4 = no change, and 7 = very much worse) [12]. This scale has also been widely used in clinical studies on GAD.

The TCM Syndrome Scale for GAD is a tailored scale for GAD and is based on the theory of TCM. It concentrates more on subjective discomfort in

| STUDY PERIOD | Enrolment | Allocation | Post-allocation |
|--------------|-----------|------------|-----------------|
| TIMEPOINT    | Day -7 / -3 | Day 0 | Day 7±2 | Day 14±2 | Day 28 ±3 | Day 56±3 |
| ENROLMENT:   |           |           |           |           |           |           |
| Eligibility screen | X | X |           |           |           |           |
| Informed consent | X |           |           |           |           |           |
| Demographic data | X |           |           |           |           |           |
| History and symptoms | X |           |           |           |           |           |
| Physical examination | X | X | X | X | X | X |
| Allocation |           | X |           |           |           |           |
| INTERVENTIONS: |           |           |           |           |           |           |
| Study group |           |           |           |           |           |           |
| Control group |           |           |           |           |           |           |
| ASSESSMENTS: |           |           |           |           |           |           |
| HAM-A | X | X | X | X | X | X |
| HAMD-17 | X | X | X | X | X | X |
| CGI-I | X | X | X | X | X | X |
| TCM Syndrome Scale for GAD | X | X | X | X | X | X |
| Pro-inflammatory cytokines | X |           |           |           |           |           |
| Safety outcomes | X |           |           |           |           |           |
| TESS |           |           |           |           |           |           |
combination with objective clinical signs. Subjective discomfort includes worry without reason, hesitation, being easily frightened, and a disinclination to talk because of a deficiency of qi. These symptoms may not be fatal but always trouble the patient seriously. Objective clinical signs focus on the complexion, color of the lips and tongue, tongue coating, and the pulse. When the patient is evaluated with this scale, the differentiation and severity of the TCM syndrome can be concluded.

Therapeutic mechanism outcomes
Pro-inflammatory cytokines, including interleukin-1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha, will be tested at baseline and the last visit. An altered cytokine balance (that is, a relatively increased pro-inflammatory response and decreased anti-inflammatory response) was found in GAD [13]. Previous clinical study showed that the anxiolytic effects of selective serotonin reuptake inhibitors may depend on their anti-inflammatory effects, proved by the reduced levels of pro-inflammatory cytokines after treatment [14]. Whether SGQR formula also has an effect on the immune balance needs to be investigated. All blood samples will be collected and centralized for tests.

Safety outcomes
Safety outcomes involve complete blood count, electrolyte panel, liver and kidney function tests, urinalysis, urine pregnancy test, and electrocardiograph. Safety outcomes will be assessed at screening time and the last visit.

Adverse events
Adverse reactions will be checked by using the Treatment Emergent Symptom Scale (TESS) at every visit [15]. If any adverse events happen during the treatment period, all details, including the time of occurrence, clinical symptoms and signs, degree, duration, laboratory findings, treatment, outcomes, and causal relationship with the treatment, will be recorded in the case report forms (CRFs). Serious adverse events will be reported to the research ethics committee, which will decide whether any additional measures should be taken.

Quality control
Before the conduction of the protocol, a range of training will be provided to all the researchers, ensuring a full understanding and mastery of the standard operating procedures. Any change to the protocol should be reported in writing to the primary researcher in Anding Hospital and can be applied only after permission. The quality of CRFs will be regularly supervised by independent investigators in Anding Hospital. Researchers will be notified in a timely fashion if any error exists.

Sample size calculation
As there is no large randomized controlled trial of SGQR formula for GAD, we referred to the experience of experts in this field. A response rate of 91% for SGQR was assumed. As to buspirone, the response rate was about 75%, according to the literature [16]. In the setting of \( \alpha = 0.05 \) and \( \beta = 0.2 \), the sample size was calculated to be 83 in each group. Given a 20% dropout rate, 17 more participants will be required in each group. In total, 200 participants will be enrolled.

Data management and analysis
CRFs will be entered by two independent researchers and supervised by a third one to ensure accuracy. Data analysis will be performed by statisticians who are blind to the randomization by using SPSS (Statistical Product and Service Solutions) Statistics for Windows, version 20.0 (IBM Corp., Armonk, NY, USA). Continuous variables will be presented as mean and standard deviation, and categorical variables will be presented as frequency or percentage. Demographic data and outcome measurements at baseline will be listed to ensure relatively even baseline levels. A two-sample t-test (if normally distributed) or non-parametric test (if not normally distributed) will be used for continuous variables when conducting baseline comparisons. The repeated measures ANOVA (analysis of variance) will be used when analyzing the primary and secondary outcomes. Chi-squared or non-parametric test will be applied for categorical variables. The analysis of efficacy will be performed in accordance with the intention-to-treat principle. Missing values will be imputed by the last observation carried forward method. Subgroup analysis will be conducted if necessary. A \( P \) value of less than 0.05 will be considered statistically significant. A mixed-effects model for repeated measures will be performed as a sensitivity analysis of the primary efficacy outcome.

Mid-term date analysis will be conducted after half of the recruitment is finished, and the principal investigator will decide whether any measure should be taken in light of the results. All of the data will be deposited in the platform developed by our team. Anding Hospital will be responsible for the data, and other researchers can have access to the data only after application and permission.
Discussion
Just like many other Chinese patent medicines, SGQR formula has been widely used in China for years, but strong clinical evidence supporting its use is still lacking, limiting its global popularization. Buspirone, a 5-hydroxytryptamine 1A receptor agonist belonging to azapirones, has been approved for the treatment of GAD in adults and has been shown to be effective [17, 18]. A Cochrane review of randomized controlled trials of azapirones in adults with GAD indicated that this class of medications is relatively well tolerated and effective [18, 19].

In this study, we chose the commonly used buspirone as the control and set a number of scientific and objective assessments. We hope that the results of this clinical trial, if successfully conducted, will provide a promising approach to treating GAD.

Trial status
The protocol version was 2.0 (August 2017). Participant recruitment began in January 2018, is ongoing at the time of this writing, and will be finished by June 2020.

Abbreviations
b.i.d.: Twice a day; CGH-I: Clinical Global Impression-Global Improvement Scale; CRF: Case report form; GAD: Generalized anxiety disorder; HAM-A: Hamilton Anxiety Rating Scale; HAM-D: Hamilton Depression Rating Scale; IL: Interleukin; SGQR: Shu-gan-qing-re; TCM: Traditional Chinese medicine; TESS: Treatment Emergent Symptom Scale; t.i.d.: Three times a day

Acknowledgements
We appreciate the efforts of all research staff participating in this trial. We also acknowledge the helpful support from all participants. The results of this clinical trial will be published in the form of academic articles by our research team.

Authors’ contributions
HXJ and HZ conceived the study. HXJ is the principal investigator. YZN contributed to the refinement of the study protocol and approved of the final manuscript.

Funding
The study is funded by Tiansheng Taifeng Pharm (Lhasa, Tibet, China) and has been approved by Beijing Anding Hospital. It is also supported by Beijing Hospitals Authority’s Ascent Plan (DFL20191901), Beijing Hospitals Authority’s Youth Programme (QML20191901), and Talents Training Fund of Beijing (2018000021469G2/92). These funding and supporting sources have no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript.

Availability of data and materials
The authors declare that all relevant data will be included in the article or supplementary files. Additional data are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Central ethical approval has been confirmed from the research ethics committee of Beijing Anding Hospital, Capital Medical University (201763-201772FS-2). Local ethical approval from other participating hospitals has also been obtained. The study will be conducted in accordance with the principles of the Declaration of Helsinki. Trial organization, data management, monitoring, and reporting will also be conducted in accordance with the guidelines for Good Clinical Practice and other regulations. Patients will be given full and adequate oral and written information about the study. The consent will be provided by the patient or a legally authorized representative.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 3 November 2019 Accepted: 19 February 2020
Published online: 14 March 2020

References
1. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet. 2006;368(9553):2156–66.
2. Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211–24.
3. Bunstein M, Beeds-ouabm K, He JP, Merikangas KR. Threshold and subthreshold generalized anxiety disorder among US adolescents: prevalence, sociodemographic, and clinical characteristics. Psychol Med. 2014;44(11):2351–62.
4. Wittchen HU, Jacob F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–79.
5. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25(1):72–90.
6. Sramek JJ, Zarotsky V, Cutler NR. Generalised anxiety disorder: treatment options. Drugs. 2002;62(11):1635–48.
7. Thompson E. Hamilton Rating Scale for Anxiety (HAM-A). Occup Med (Lond). 2015;65(7):601.
8. Zimmerman M, Martin J, Clark H, McGonigal P, Harris L, Holst CG, et al. Measuring anxiety in depressed patients: A comparison of the Hamilton anxiety rating scale and the DSM-5 Anxious Distress Specifier Interview. J Psychiatr Res. 2017;93:59–63.
9. Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol. 2007;3:137–58.
10. Leucht S, Fennema H, Engel R, Kaspers-Jansen M, Lepping P, Szegedi A. What does the HAMD mean? J Affect Disord. 2013;148(2–3):243–8.
11. Boessen R, Goenwoord RH, Knol MJ, Grobber DE, Roos KC. Comparing HAMD(17) and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials. J Affect Disord. 2013;145(3):363–9.
12. Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008;25(3):182–9.
13. Hou R, Garner M, Holmes C, Osmund C, Teeling J, Lui L, et al. Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. Brain Behav Immun. 2017;62:212–8.
14. Hou R, Ye G, Liu Y, Chen X, Pan M, Zhu F, et al. Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder. Brain Behav Immun. 2019;81:105–10.
15. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry. 2006;67(7):1042–6.
16. Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M. Kava-Kava extract LI 150 is as effective as Oppiranol and Buspirone in Generalised Anxiety Disorder—an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine. 2003;10(Suppl 4):38–49.
17. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93–107.
18. Stawrn JR, Geracioti L, Rajdev N, Clemenza K, Levine A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018;19(10):1057–70.
19. Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de Lima MS, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006;3:CD006155.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.